Four additional sites open for recruitment in Oncoinvent’s Phase 2 trial

Oncoinvent has activated four additional sites in its randomized Phase 2 trial of Radspherin® for peritoneal carcinomatosis from ovarian cancer and enrolled the first patient at a newly opened site (ClinicalTrials.gov: NCT06504147). The trial — comparing progression-free survival for patients receiving intraperitoneal Radspherin® after complete surgical resection versus surgery alone — will recruit across 11 sites in Norway (1), Spain (5), Belgium (1), the UK (2), the US (1) and Italy (1); earlier Phase 1/2a safety data showed Radspherin® was well tolerated with no dose-limiting toxicity at the recommended 7 MBq. The update signals continued clinical development momentum and de-risking milestones that may be relevant to investors in ONCIN.

Analysis

Market structure: Oncoinvent (ONCIN) site activations and first new-site enrollment materially de-risks Phase 2 enrollment velocity — accelerating from 6 to 11 sites suggests recruitment could hit a meaningful inflection in 6–12 months, improving probability of a clean primary PFS readout. Direct winners: ONCIN equity and niche radiopharma service providers (isotope suppliers, specialty CDMOs). Losers: broader non-radiopharma ovarian oncology developers may cede investor attention and short-term capital.

Risk assessment: Key tail risks are regulatory/safety signals from alpha emitter therapy (10–20% chance of significant setback) and radium‑224 supply/manufacturing bottlenecks causing trial delays of 3–12+ months. Near-term (days–weeks) volatility will center on enrollment updates; medium-term (6–18 months) hinges on DSMB/interim safety and enrollment pace; long-term (12–36 months) depends on PFS data and reimbursement signals. Hidden dependencies include single-site manufacturing capacity in Oslo and third‑party isotope logistics.

Trade implications: Tactical trade is concentrated, size‑limited exposure to ONCIN: structured option spreads (12–18 month call spreads) to capture binary upside while capping premium, and a relative hedge vs XBI to mute sector drawdowns. Cross-asset: limited bond/FX impact, but small-cap biotech convertibles and equity vol should widen on any negative readouts — favor buying protection if leverage is used.

Contrarian angles: Consensus may underprice operational constraints (supply/manufacturing) while overvaluing early site activations as proof of clinical success; historical radiopharma rollouts show pronounced binary outcomes (either rapid re-rating or 40–70% drawdown on safety/failure). Unintended consequence: accelerated enrollment could reveal unexpected safety signals faster — scale exposure conservatively and time add‑ons to enrollment milestones.

Key Decisions for Investors

• Establish a tactical 2–3% long position in Oncoinvent (ONCIN) within 30 days to capture Phase 2 derisking; target a 2.0–3.0x upside on positive enrollment/DSMB signals within 12–18 months; implement a 30–35% hard stop-loss.
• Buy a 12–18 month call spread on ONCIN sized to 1% of portfolio (buy ATM LEAP call, sell ~30% OTM call) to limit premium outlay while retaining upside to a positive PFS trajectory or encouraging enrollment milestones.
• Implement a pair-hedge: long ONCIN 2% funded by short 1% of iShares Biotechnology ETF (XBI) for 6–12 months to hedge sector volatility and idiosyncratic biotech downside during trial readouts.
• Reduce exposure to broad radiopharma peer TLX.AX (Telix) by 1–2% relative to benchmark allocation and redeploy into ONCIN if enrollment achieves 75% of target sites activated and rolling enrollment <9 months—reverse if missed by >3 months.
• Set event-driven rules: add incremental 1–2% to ONCIN only after (a) public DSMB safety sign-off or (b) confirmation of radium‑224 supply contract/backup within 90 days; exit or cut to zero on any Grade ≥3 unexpected alpha-related toxicity or >3 month enrollment delay.